Compare Cytokinetics Inc (CYTK) vs Monolithic Power Systems Inc (MPWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Monolithic Power Systems Inc — how do they compare? Cytokinetics Inc trades at $81.99 (market cap $11.12B), while Monolithic Power Systems Inc trades at $1,397.43 (market cap $67.62B). The key difference: Monolithic Power Systems Inc is far larger — about 6.1× Cytokinetics Inc's market cap, and Monolithic Power Systems Inc pays a 0.58% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | MPWR | |
|---|---|---|
Market Cap | $11.12B | $67.62B |
Sector | Technology | Utilities |
52-Week High | $87.26 | $1.69K |
52-Week Low | $33.23 | $711.24 |
Enterprise Value | $11.59B | $66.28B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
Monolithic Power Systems (MPWR) trades at $1,291.38, down 4.54% on the day, amid a bearish technical signal despite strong fundamentals. The stock shows robust profitability with 22.98% net income margin and has beaten earnings estimates for three consecutive quarters. Analyst consensus remains strongly bullish with 88% buy ratings and a $1,760 price target, representing significant upside potential from current levels.
The stock presents a compelling growth opportunity driven by AI infrastructure demand and power semiconductor trends, though elevated valuation multiples and ongoing legal investigations pose risks. Technical indicators suggest near-term weakness, but strong institutional support and consistent earnings performance support the long-term bullish case for investors seeking exposure to semiconductor growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Monolithic Power Systems Inc
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →
